Solventum

SolventumSOLVEarnings & Financial Report

NYSE · Health Care · Health Care Technology

Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.

SOLV Q1 FY2026 Key Financial Metrics

Revenue

$2.0B

Gross Profit

$1.1B

Operating Profit

$81.0M

Net Profit

$13.0M

Gross Margin

54.7%

Operating Margin

4.0%

Net Margin

0.6%

YoY Growth

-3.0%

EPS

$0.07

Solventum Q1 FY2026 Financial Summary

Solventum reported revenue of $2.0B (down 3.0% YoY) for Q1 FY2026, with a net profit of $13.0M (0.6% margin). Cost of goods sold was $910.0M, operating expenses totaled $1.0B.

Key Financial Metrics

Total Revenue$2.0B
Net Profit$13.0M
Gross Margin54.7%
Operating Margin4.0%
Report PeriodQ1 FY2026

Revenue Breakdown

Solventum Q1 FY2026 revenue of $2.0B breaks down across 5 segments, led by Infection Prevention and Surgical Solutions at $737.0M (36.7% of total).

SegmentRevenue% of Total
Infection Prevention and Surgical Solutions$737.0M36.7%
Advanced Wound Care$497.0M24.8%
Dental Solutions$354.0M17.6%
Health Information Systems$342.0M17.0%
All Other 4$76.0M3.8%

Solventum Revenue by Segment — Quarterly Trend

Solventum revenue by segment across the last 4 reported quarters, showing how each business line (such as Infection Prevention and Surgical Solutions and Advanced Wound Care) has evolved quarter over quarter.

SegmentQ1 FY2026Q4 FY2025Q3 FY2025Q2 FY2025
Infection Prevention and Surgical Solutions$737.0M
Advanced Wound Care$497.0M$467.0M
Dental Solutions$354.0M
Health Information Systems$342.0M
All Other 4$76.0M

Solventum Annual Revenue by Year

Solventum annual revenue history includes year-by-year totals (for example, 2025 revenue was $8.3B).

YearAnnual Revenue
2025$8.3Bvs 2024
2024$8.3B

Solventum Quarterly Revenue & Net Profit History

Solventum results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q1 FY2026$2.0B-3.0%$13.0M0.6%
Q4 FY2025$2.0B-3.7%$63.0M3.2%
Q3 FY2025$2.1B+0.7%$1.3B60.4%
Q2 FY2025$2.2B+3.8%$90.0M4.2%
Q1 FY2025$2.1B+2.7%$137.0M6.6%
Q4 FY2024$2.1B$31.0M1.5%
Q3 FY2024$2.1B+0.4%$122.0M5.9%
Q2 FY2024$2.1B+0.2%$89.0M4.3%

Income Statement

Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Revenue$2.08B$2.08B$2.08B$2.07B$2.16B$2.10B$2.00B$2.01B
YoY Growth0.2%0.4%N/A2.7%3.8%0.7%-3.7%-3.0%

Balance Sheet

Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Assets$14.58B$14.74B$14.46B$14.53B$15.07B$13.97B$14.29B$14.10B
Liabilities$11.71B$11.55B$11.50B$11.27B$11.43B$8.99B$9.24B$9.13B
Equity$2.87B$3.19B$2.96B$3.26B$3.65B$4.99B$5.05B$4.97B

Cash Flow

Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Operating CF$355.0M$169.0M$219.0M$29.0M$169.0M$76.0M$95.0M